Results 231 to 240 of about 216,339 (397)

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

New England Journal of Medicine, 2011
R. Burger, M. Brady, M. Bookman, G. Fleming, B. Monk, Helen Q. Huang, R. Mannel, H. Homesley, J. Fowler, B. Greer, M. Boente, M. Birrer, S. Liang   +12 more
semanticscholar   +1 more source

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem, Esra Inci, Martin Breimer, Sofia Töyrä Silfverswärd, Madeleine Zetterberg, Marita Andersson Grönlund   +5 more
wiley   +1 more source

Economic evaluation of three domestic bevacizumab biosimilars and the original bevacizumab for treating nonsquamous non-small cell lung cancer in china: a cost-effectiveness analysis. [PDF]

Cost Eff Resour Alloc
Zhang Y, Zhou T, Wu N, Bai Z, Wei J, Cai N, Xu S.   +6 more
europepmc   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, EarlyView.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer. [PDF]

Front Immunol
Simayi N, Li J, Hu J, Jia N, Wan R, Xie J, Huang W.   +6 more
europepmc   +1 more source

Treatment of a vasoproliferative tumour with intravitreal bevacizumab (Avastin) [PDF]

, 2007
Nihal Kenawy, C Groenwald, Bertil Damato
openalex   +1 more source

Comparison of the Efficacy of Different First‐Line Therapies for EGFR L858R‐Mutated NSCLC Patients With Brain Metastases

Cancer Science, EarlyView.
The combination of third‐generation EGFR‐TKIs with chemotherapy shows enhanced efficacy in patients with EGFR 21L858R mutation and BMs compared to other treatments. Future prospective clinical trials are warranted to assess this combination in this population.
Jing Chen, Yin Pan, Baishen Zhang, Meichen Li, Hui Yu, Mingjie Yu, Likun Chen   +6 more
wiley   +1 more source

Cerebral radiation necrosis successfully treated with high-dose bevacizumab. [PDF]

Respir Med Case Rep
Kugimiya K, Tsubouchi H, Saito K, Kadota Y, Azuma M, Sakai K, Oda Y, Sumiyoshi M, Yanagi S, Miyazaki T.   +9 more
europepmc   +1 more source

Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis [PDF]

, 2007
Muthu Selvakumaran, Kang Yao, Michael D. Feldman, Peter J. O’Dwyer   +3 more
openalex   +1 more source

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Journal of Clinical Oncology, 2009
H. Friedman, M. Prados, P. Wen, T. Mikkelsen, D. Schiff, L. Abrey, W. Yung, N. Paleologos, M. Nicholas, R. Jensen, J. Vredenburgh, Jane E. Huang, M. Zheng, T. Cloughesy   +13 more
semanticscholar   +1 more source